Somatic Cell Genome Editing Consortium

The Somatic Cell Genome Editing (SCGE) Consortium is an NIH Common Fund program that aims to develop safe and effective methods to perform gene editing to treat genetic diseases in somatic cells. For Phase 2, the goal of the SCGE program is to accelerate the development of genome editing therapies into clinic. There are four initiatives to help achieve this goal: 1) Developing technologies and assays for safety and efficacy studies 2) Optimizing genome editing-based therapeutic leads to support advancement towards clinical trials 3) Supporting novel genome editing clinical trials for more than one disease 4) Fostering collaboration and share new technologies and protocols with the public and research community The SCGE is funded by The NIH Common Fund. This account is managed by the TCDC. Reposts and likes are not endorsements.